Medtronic (NYSE:MDT) had its target price hoisted by BTIG Research to $120.00 in a research report report published on Wednesday, The Fly reports. BTIG Research currently has a buy rating on the medical technology company’s stock.

Several other research analysts have also commented on MDT. ValuEngine lowered shares of Medtronic from a buy rating to a hold rating in a research note on Thursday, August 1st. UBS Group lifted their price objective on shares of Medtronic to $112.00 and gave the stock a buy rating in a research note on Friday, June 14th. Cowen reaffirmed an outperform rating and set a $111.00 price objective (up from $99.00) on shares of Medtronic in a research note on Wednesday, August 14th. Northland Securities reaffirmed a hold rating and set a $100.00 price objective on shares of Medtronic in a research note on Wednesday. Finally, Barclays lifted their price objective on shares of Medtronic from $104.00 to $110.00 and gave the stock an overweight rating in a research note on Thursday, July 11th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Medtronic has an average rating of Buy and a consensus target price of $113.55.

MDT stock opened at $106.05 on Wednesday. The firm has a fifty day moving average price of $101.64 and a 200 day moving average price of $94.06. Medtronic has a fifty-two week low of $81.66 and a fifty-two week high of $109.70. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.15 and a current ratio of 2.67. The firm has a market cap of $144.62 billion, a PE ratio of 20.32, a price-to-earnings-growth ratio of 2.65 and a beta of 0.67.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 20th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.08. The firm had revenue of $7.49 billion during the quarter, compared to analyst estimates of $7.40 billion. Medtronic had a net margin of 14.41% and a return on equity of 14.36%. Medtronic’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the firm posted $1.17 earnings per share. On average, equities analysts predict that Medtronic will post 5.56 EPS for the current year.

In other news, SVP Richard Kuntz sold 3,438 shares of Medtronic stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $101.12, for a total transaction of $347,650.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Bradley E. Lerman sold 4,000 shares of Medtronic stock in a transaction on Monday, August 5th. The stock was sold at an average price of $100.31, for a total value of $401,240.00. Following the sale, the senior vice president now owns 52,906 shares of the company’s stock, valued at $5,307,000.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,701 shares of company stock valued at $9,318,744. Corporate insiders own 0.28% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Krane Funds Advisors LLC bought a new stake in shares of Medtronic during the second quarter worth $25,000. Redhawk Wealth Advisors Inc. bought a new stake in shares of Medtronic in the second quarter valued at about $34,000. Rocky Mountain Advisers LLC raised its holdings in shares of Medtronic by 100.0% in the second quarter. Rocky Mountain Advisers LLC now owns 400 shares of the medical technology company’s stock valued at $39,000 after acquiring an additional 200 shares in the last quarter. Mackey Komara & Dankovich LLC bought a new stake in shares of Medtronic in the first quarter valued at about $38,000. Finally, Transamerica Financial Advisors Inc. bought a new stake in shares of Medtronic in the second quarter valued at about $48,000. Institutional investors and hedge funds own 80.62% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Story: How does a security become overbought?

The Fly

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.